Literature DB >> 21769693

Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients.

Kei Suzuki1, Kyuichi Kadota, Camelia S Sima, Michel Sadelain, Valerie W Rusch, William D Travis, Prasad S Adusumilli.   

Abstract

This study aims to determine whether a semi-quantitative assessment of inflammatory response in tumor and stroma on routine hematoxylin and eosin-stained (H&E) slides can predict survival in patients with epithelioid malignant pleural mesothelioma (MPM). H&E sections of 175 epithelioid MPM specimens from a single institution (1989-2009) were reviewed. Patients who received neoadjuvant chemotherapy were excluded from analysis. Each tumor was histologically assessed for acute and chronic inflammatory response both within the tumor and the stromal component. Inflammatory response was graded: low (none to mild infiltrate) or high (moderate to severe infiltrate). Log-rank test and Cox proportional hazards regression were used to investigate the association between the degree of inflammation (acute/tumor, acute/stroma, chronic/tumor, and chronic/stroma) and overall survival (OS). Patients with high chronic inflammatory response in stroma (n = 59) had improved survival compared to low (n = 116) (median OS = 19.4 vs. 15.0 months, P = 0.01). This prognostic stratification remained significant in stage III patients (median OS = 16.0 vs. 9.3 months, P = 0.03). In multivariate analysis, chronic inflammation in stroma was an independent predictor of survival (HR = 0.659, 95% CI 0.464-0.937, P = 0.02). While high degree of chronic inflammatory cell infiltration in the stromal component was associated with improved overall survival, degree of other inflammatory responses did not show significant correlation with OS. Our study for the first time investigates inflammatory response in tumor and stroma and not only suggests the prognostic value of inflammatory response in epithelioid MPM but also provides rationale for investigation of immunotherapy to benefit epithelioid MPM patients.

Entities:  

Mesh:

Year:  2011        PMID: 21769693      PMCID: PMC6250069          DOI: 10.1007/s00262-011-1073-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  25 in total

1.  Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer.

Authors:  Xin An; Pei-Rong Ding; Yu-Hong Li; Feng-Hua Wang; Yan-Xia Shi; Zhi-Qiang Wang; You-Jian He; Rui-Hua Xu; Wen-Qi Jiang
Journal:  Biomarkers       Date:  2010-09       Impact factor: 2.658

Review 2.  Paradoxical roles of the immune system during cancer development.

Authors:  Karin E de Visser; Alexandra Eichten; Lisa M Coussens
Journal:  Nat Rev Cancer       Date:  2006-01       Impact factor: 60.716

3.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

4.  Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients.

Authors:  D J Sugarbaker; R M Flores; M T Jaklitsch; W G Richards; G M Strauss; J M Corson; M M DeCamp; S J Swanson; R Bueno; J M Lukanich; E H Baldini; S J Mentzer
Journal:  J Thorac Cardiovasc Surg       Date:  1999-01       Impact factor: 5.209

5.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.

Authors:  Sahar M A Mahmoud; Emma Claire Paish; Desmond G Powe; R Douglas Macmillan; Matthew J Grainge; Andrew H S Lee; Ian O Ellis; Andrew R Green
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

6.  High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy.

Authors:  Steven C H Kao; Nick Pavlakis; Rozelle Harvie; Janette L Vardy; Michael J Boyer; Nico van Zandwijk; Stephen J Clarke
Journal:  Clin Cancer Res       Date:  2010-10-18       Impact factor: 12.531

7.  Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer.

Authors:  Khalid I Al-Shibli; Tom Donnem; Samer Al-Saad; Magnus Persson; Roy M Bremnes; Lill-Tove Busund
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

8.  Lymphocytic infiltration of pleural mesothelioma and its significance for survival.

Authors:  R A Leigh; I Webster
Journal:  S Afr Med J       Date:  1982-06-26

9.  Malignant mesothelioma-associated antigens recognized by tumor-infiltrating B cells and the clinical significance of the antibody titers.

Authors:  Yoshiki Shigematsu; Takeshi Hanagiri; Koji Kuroda; Tetsuro Baba; Makiko Mizukami; Yoshinobu Ichiki; Manabu Yasuda; Mitsuhiro Takenoyama; Kenji Sugio; Kosei Yasumoto
Journal:  Cancer Sci       Date:  2009-04-30       Impact factor: 6.716

10.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

View more
  39 in total

Review 1.  Immunotherapy for malignant pleural mesothelioma: current status and future directions.

Authors:  Jordan Dozier; Hua Zheng; Prasad S Adusumilli
Journal:  Transl Lung Cancer Res       Date:  2017-06

2.  Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.

Authors:  Jonathan Villena-Vargas; Prasad S Adusumilli
Journal:  Ann Cardiothorac Surg       Date:  2012-11

3.  Inflammation in malignant mesothelioma - friend or foe?

Authors:  Anthony Linton; Nico van Zandwijk; Glen Reid; Stephen Clarke; Christopher Cao; Steven Kao
Journal:  Ann Cardiothorac Surg       Date:  2012-11

4.  The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.

Authors:  Hideki Ujiie; Kyuichi Kadota; Jun-Ichi Nitadori; Joachim G Aerts; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Lee M Krug; Prasad S Adusumilli
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

5.  Current issues in malignant pleural mesothelioma evaluation and management.

Authors:  Jing Ai; James P Stevenson
Journal:  Oncologist       Date:  2014-07-24

Review 6.  Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma.

Authors:  Adam J Bograd; Kei Suzuki; Eva Vertes; Christos Colovos; Eduardo A Morales; Michel Sadelain; Prasad S Adusumilli
Journal:  Cancer Immunol Immunother       Date:  2011-09-13       Impact factor: 6.968

7.  Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma.

Authors:  Prasad S Adusumilli
Journal:  Cancer       Date:  2014-07-02       Impact factor: 6.860

8.  Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma: Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor.

Authors:  Kyuichi Kadota; Jun-Ichi Nitadori; Hideki Ujiie; Daniel H Buitrago; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Prasad S Adusumilli
Journal:  J Thorac Oncol       Date:  2015-09       Impact factor: 15.609

9.  Novel immunotherapy clinical trials in malignant pleural mesothelioma.

Authors:  Zachary E Tano; Navin K Chintala; Xiaoyu Li; Prasad S Adusumilli
Journal:  Ann Transl Med       Date:  2017-06

Review 10.  Surgical immune interventions for solid malignancies.

Authors:  Masha Zeltsman; Marissa Mayor; David R Jones; Prasad S Adusumilli
Journal:  Am J Surg       Date:  2016-07-18       Impact factor: 2.565

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.